Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-7012 in Healthy Adults
NCT07749651Phase 1Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial of SHR-7012 in cutaneous lupus erythematosus (CLE) (5 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Adverse Events at Day 141. Started Aug 2026; status: recruiting.
02
Drugs
SHR-7012
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT07749651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07749651.